Screener
Bio-Rad Laboratories BIO Long-Term Debt
Long-Term Debt at other companies
Other financials
Where this comes from
Reported directly by Bio-Rad Laboratories in its filing.
Tagged under the XBRL concept us-gaap:LongTermDebtNoncurrent.
The source filing: Bio-Rad Laboratories’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 4:19 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0000012208-26-000035
| LIABILITIES AND STOCKHOLDERS’ EQUITY | March 31, 2026 / (Unaudited) | December 31, 2025 |
|---|---|---|
| Current operating lease liabilities | 36.2 | 36.1 |
| Other current liabilities | 153.9 | 141.7 |
| Total current liabilities | 917.0 | 517.0 |
| Long-term debt, net of current maturities | 802.9 | 1,201.7 |
| Deferred income taxes | 881.8 | 1,059.4 |
| Operating lease liabilities | 138.6 | 145.7 |
| Other long-term liabilities | 198.4 | 199.1 |
| Total liabilities | 2,938.7 | 3,122.9 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Bio-Rad Laboratories's long-term debt?
- Bio-Rad Laboratories (BIO) reported long-term debt of $802.9M in Q1 2026.
- How has Bio-Rad Laboratories's long-term debt changed year-over-year?
- Bio-Rad Laboratories's long-term debt decreased by 33.1% year-over-year, from $1.2B to $802.9M.
- What is the long-term trend for Bio-Rad Laboratories's long-term debt?
- Over 5 years (2020 to 2025), Bio-Rad Laboratories's long-term debt has grown at a 150.2% compound annual growth rate (CAGR), from $12.26M to $1.2B.
- What does long-term debt mean?
- Bonds, term loans, notes payable, and other borrowings with maturities beyond one year — the primary long-term financing source.
Ask your AI about Bio-Rad Laboratories's long-term debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude